A population PK study into teicoplanin in intensive care and haematology patients * a strategy towards model informed precision dosing (PLATO)

A population PK study into teicoplanin in intensive care and haematology patients * a strategy towards model informed precision dosing (PLATO) - PLATO

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON49412

Enrollment

Registered

2020-11-30

Start date

2019-12-23

Completion date

Unknown

Last updated

2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacteriele infectie

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. The patient is admitted to the ICU of the haematology department 2. The patient is at least 18 years of age on the day of inclusion 3. Is treated with teicoplanin as a part of standard care 4. Is able and willing to sign the Informed Consent form

Exclusion criteria

Exclusion criteria: 1. Has previously participated in this study 2. Patient receives any form of RRT other than continuous venovenous hemofiltration (CVVH).

Design outcomes

Primary

Measure	Time frame
To develop a population pharmacokinetic model of teicoplanin in Intensive Care and Haematology patients	—

Secondary

Measure	Time frame
- To estimate the influence of renal function on the teicoplanin clearance using different renal biomarkers. - To investigate the impact of serum albumin on bound and unbound teicoplanin concentrations. - To develop a limited sampling strategy for estimating the area under the concentration time curve of teicoplanin.	—

Countries

Netherlands

Outcome results